Abeona Therapeutics Inc.

Contributing Author

Recent Articles by Abeona Therapeutics Inc.

Feb-09	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ABEO GlobeNewswire
Dec-31	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ABEO GlobeNewswire
Dec-15	Abeona Therapeutics Announces Appointment of Mohamad Tabrizi as Chief Business Officer ABEO -5.22% GlobeNewswire
Dec-11	Abeona Therapeutics Announces New Qualified Treatment Center for ZEVASKYN in Texas ABEO GlobeNewswire
Dec-08	Abeona Therapeutics Announces First Patient Treatment with ZEVASKYN Gene Therapy ABEO +5.34% GlobeNewswire
Dec-01	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ABEO -5.72% GlobeNewswire
Nov-12	Abeona Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates ABEO +18.47% GlobeNewswire
Nov-07	Abeona Therapeutics Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation ABEO GlobeNewswire
Nov-03	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ABEO GlobeNewswire
Oct-30	Abeona Therapeutics Announces Permanent J-Code for ZEVASKYN (prademagene zamikeracel) ABEO GlobeNewswire
Oct-20	Abeona Therapeutics Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs ABEO GlobeNewswire
Oct-13	Abeona Therapeutics Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program ABEO GlobeNewswire
Oct-01	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ABEO GlobeNewswire
Sep-02	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ABEO GlobeNewswire
Aug-29	Abeona Therapeutics Announces Participation in Upcoming Investor Conferences ABEO GlobeNewswire
Aug-14	Abeona Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates ABEO +10.21% GlobeNewswire
Aug-01	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ABEO GlobeNewswire
Jul-15	ZEVASKYN Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area ABEO GlobeNewswire
Jul-02	Abeona Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million ABEO +5.39% GlobeNewswire
Jul-01	Abeona Therapeutics Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy ABEO GlobeNewswire
Jul-01	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ABEO GlobeNewswire
Jun-30	Abeona Therapeutics added to Membership of U.S. Small-cap Russell 2000 Index and Broad-market Russell 3000 Index ABEO GlobeNewswire
Jun-24	Abeona Therapeutics Announces Publication in The Lancet of Phase 3 VIITAL Study Data in Recessive Dystrophic Epidermolysis Bullosa ABEO GlobeNewswire
Jun-02	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ABEO GlobeNewswire
May-30	Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference ABEO GlobeNewswire
May-15	Abeona Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates ABEO +7.42% GlobeNewswire
May-14	UPDATE -- Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYN Gene Therapy to Treat Wounds in Painful Skin Disorder ABEO GlobeNewswire
May-14	Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder ABEO GlobeNewswire
May-14	Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYN Gene Therapy to Treat Wounds in Painful Skin Disorder ABEO GlobeNewswire
May-12	Abeona Therapeutics Enters into Agreement to Sell Priority Review Voucher for $155 Million ABEO +6.26% GlobeNewswire
May-07	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ABEO -8.51% GlobeNewswire

Abeona Therapeutics Inc.

Recent Articles by Abeona Therapeutics Inc.

Upgrade your FINVIZ experience